ROCKVILLE, MD and SHENZHEN, CHINA, September 30, 2024—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, a
September 30, 2024
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, September 19, 2024—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, a
September 19, 2024
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, September 10, 2024—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, a
September 10, 2024
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, August 29, 2024—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabol
August 29, 2024
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, June 21, 2024—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, annou
June 21, 2024
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, June4, 2024—HighTide Therapeutics, Inc. (Stock Code: 2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced to
June 04, 2024
Learn More
We will contact you as soon as possible
© 2024 HighTide Therapeutics, Inc.